Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986446 in Healthy Participants
NCT06084598Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRX005 in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events (AEs), Number of participants with vital sign abnormalities and 4 more. Started Oct 2023; status: completed.
02
Drugs
PRX005
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06084598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084598.